{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:22:47Z","timestamp":1767705767286,"version":"3.41.2"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>Innovation refers to the introduction of a product, a process, a service or a solution resulting in something new or significantly improved compared to the already available alternatives. In the clinical context, it is strictly related to the identification of a new added value in terms of quality, therapeutic efficacy and safety. Over the years several innovative approaches have been introduced in the clinical practice, revolutionizing the treatment and the management of important rhinologic conditions. Innovative tools, including new drugs, biomaterials, and mobile applications seem to be able to improve the clinical outcomes and the quality of life of many patients affected by (often relapsing) rhinologic diseases. Among the main modern pharmacological innovations, mention must be made of the biological drugs like monoclonal antibodies (mAbs). Recently, new mAbs have been introduced and investigated as useful arms in the treatment of some inflammatory\/infectious or oncological diseases affecting the nasal cavities and paranasal sinuses. The already approved or still investigated mAbs work inhibiting different type 2 inflammation pathways, including those mediated by IgE (omalizumab), IL-4\/IL-13 (dupilumab), and IL-5 (mepolizumab). Moreover, considering the higher expression of PD-L1 in nasopharyngeal carcinoma, the use of PD-1 inhibitors, such as nivolumab, or a dual CTLA-4\/PD-1 blockade (ipilimumab plus nivolumab) appear to be an effective strategy for the treatment of this cancer form. The implants with bio-absorbable biomaterials represent new interesting available technological innovations. Moreover, advanced technologies such as the artificial intelligence, the machine learning as well as the augmented or virtual reality have also proved useful in rhinologic field with main impacts on precision medicine and surgery. Finally, the development and use of mobile-Health tools represent a winning strategy in monitoring of the therapy success, safety and tolerability as well as the progress of chronic disease including chronic rhinosinusitis with nasal polyps. Supporting the research of innovative tools and strategies (including pharmacological, technologic, or digital ones) is essential to improve the management of chronic diseases that significantly affect the patients' quality of life.<\/jats:p>","DOI":"10.3389\/falgy.2021.732909","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T05:54:47Z","timestamp":1639547687000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacological, Technological, and Digital Innovative Aspects in Rhinology"],"prefix":"10.3389","volume":"2","author":[{"given":"Rosanna","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Motta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Rafaniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Della Corte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"De Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Motta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fphar.2019.00111","article-title":"The new paradigms in clinical research: from early access programs to the novel therapeutic approaches for unmet medical needs","volume":"10","author":"Scavone","year":"2019","journal-title":"Front Pharmacol."},{"key":"B3","unstructured":"Allegato 1 Criteri Per La Valutazione Dell'innovativita'.2021"},{"key":"B4","unstructured":"del NazarenoL\n          Farmindustria Centro Studi.2021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2017.11.002","article-title":"Strengths, weaknesses and future challenges of biosimilars' development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice","volume":"126","author":"Scavone","year":"2017","journal-title":"Pharmacol Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/19420862.2017.1343709","article-title":"Safety of biologics therapy: monoclonal antibodies, cytokines, fusion proteins, hormones, enzymes, coagulation proteins, vaccines, botulinum toxins","volume":"9","author":"Mahler","year":"2017","journal-title":"MAbs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1021\/acschemneuro.9b00112","article-title":"Predictions and statistics for the best-selling drugs globally and in the United States in 2018 and a look forward to 2024 projections","volume":"10","author":"Lindsley","year":"2019","journal-title":"ACS Chem Neurosci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1111\/bph.15072","article-title":"Current pharmacological treatments for COVID-19: what's next?","volume":"177","author":"Scavone","year":"2020","journal-title":"Br. J Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15452","article-title":"Therapeutic strategies to fight COVID-19: which is the status artis?","author":"Scavone","year":"2021","journal-title":"Br J Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21249477","article-title":"Monoclonal antibodies and airway diseases","volume":"21","author":"Lyly","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11882-018-0776-8","article-title":"Precision medicine in chronic rhinosinusitis with nasal polyps","author":"Avdeeva","year":"2018","journal-title":"Curr Allergy Asthma Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaci.2018.12.986","article-title":"Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology","volume":"143","author":"Dietz de Loos","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22020910","article-title":"Advances in the knowledge of the underlying airway remodeling mechanisms in chronic rhinosinusitis based on the endotypes: a review","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"CD013513","DOI":"10.1002\/14651858.CD013513.pub3","article-title":"Biologics for chronic rhinosinusitis","volume":"2021","author":"Chong","year":"2021","journal-title":"Cochrane Database Syst Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinol J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jaci.2020.04.040","article-title":"Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype","volume":"146","author":"Delemarre","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4193\/Rhin17.156","article-title":"Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review","volume":"56","author":"Tsetsos","year":"2018","journal-title":"Rhinol J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nri3807","article-title":"Type 2 inflammation in asthma-present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000514262","article-title":"Real-life experience of monoclonal antibody treatments in chronic rhinosinusitis with nasal polyposis","volume":"2021","author":"Meier","year":"2021","journal-title":"Int Arch Allergy Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eng.2020.06.029","article-title":"Current state of monoclonal antibody therapy for allergic diseases","volume":"6","author":"Chen","year":"2021","journal-title":"Engineering."},{"key":"B24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12974-017-1001-8","article-title":"Novel pathomechanisms in inflammatory neuropathies","volume":"14","author":"Schafflick","year":"2017","journal-title":"J Neuroinflammation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/0003489417731782","article-title":"Anti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis","volume":"126","author":"Rivero","year":"2017","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse","year":"2018","journal-title":"Front Med."},{"key":"B29","unstructured":"2021"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"97","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40265-016-0583-2","article-title":"Reslizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1517\/14712598.2015.1090972","article-title":"Update on reslizumab for eosinophilic asthma","volume":"15","author":"Cardet","year":"2015","journal-title":"Expert Opin Biol Ther."},{"key":"B34","unstructured":"2021"},{"key":"B35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11882-019-0850-x","article-title":"Precision medicine in rhinosinusitis","author":"Vlastos","year":"2019","journal-title":"Curr Allergy Asthma Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"cea","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial","volume":"2021","author":"Tversky","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"1","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy."},{"key":"B40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"J Am Med Assoc Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1177\/0003489418802288","article-title":"Intralesional bevacizumab for the treatment of recurrent sinonasal hemangioma","volume":"127","author":"Kinzinger","year":"2018","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2020.00830","article-title":"Immune checkpoint inhibitors and immune-related adverse drug reactions: data from Italian Pharmacovigilance Database","volume":"11","author":"Ruggiero","year":"2020","journal-title":"Front Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)","volume":"388","author":"Ma","year":"2018","journal-title":"J Clin Oncol."},{"key":"B46","article-title":"Combination ipilimumab and nivolumab in recurrent\/metastatic nasopharyngeal carcinoma (R\/M NPC) updated efficacy and safety analysis of NCT03097939","author":"Kao","year":"2020","journal-title":"ESMO Asia Vir Cong"},{"key":"B47","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/pharmaceutics13020246","article-title":"Pharmaceutics current perspective on nasal delivery systems for chronic rhinosinusitis","volume":"13","author":"Tai","year":"2021","journal-title":"Pharmaceutics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/alr.21963","article-title":"Safety and efficacy of a bioabsorbable fluticasone propionate\u2013eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial","volume":"7","author":"Adriaensen","year":"2017","journal-title":"Int Forum Allergy Rhinol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/alr.21426","article-title":"RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis","volume":"4","author":"Han","year":"2014","journal-title":"Int Forum Allergy Rhinol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/alr.21741","article-title":"RESOLVE: bioabsorbable steroid-eluting sinus implants for in-office treatment of recurrent sinonasal polyposis after sinus surgery: 6-month outcomes from a randomized, controlled, blinded study","volume":"6","author":"Forwith","year":"2016","journal-title":"Int Forum Allergy Rhinol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1002\/alr.22213","article-title":"Effects of mometasone furoate\u2013impregnated biodegradable nasal dressing on endoscopic appearance in healing process following endoscopic sinus surgery: a randomized, double-blind, placebo-controlled study","volume":"8","author":"Zhao","year":"2018","journal-title":"Int Forum Allergy Rhinol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/17512433.2018.1549485","article-title":"Mometasone furoate sinus implant\u2013a new targeted approach to treating recurrent nasal polyp disease","volume":"11","author":"Shen","year":"2018","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/1945892419850924","article-title":"In-office placement of mometasone furoate sinus implants for recurrent nasal polyps: a pooled analysis","volume":"33","author":"Stolovitzky","year":"2019","journal-title":"Am J Rhinol Allergy."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1002\/lary.28388","article-title":"Efficacy and safety of steroid-impregnated implants following sinus surgery: a meta-analysis","volume":"130","author":"Li","year":"2020","journal-title":"Laryngoscope."},{"key":"B55","doi-asserted-by":"publisher","first-page":"941","DOI":"10.18553\/jmcp.2019.18285","article-title":"Budget impact of a steroid-eluting sinus implant versus sinus surgery for adult chronic sinusitis patients with nasal polyps","volume":"25","author":"Ernst","year":"2019","journal-title":"J Manag Care Spec Pharm."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1038\/bjc.2013.663","article-title":"Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer","volume":"109","author":"Homma","year":"2013","journal-title":"Br J Cancer."},{"key":"B57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13005-021-00285-z","article-title":"Imaging predictor of ophthalmic involvement in maxillary sinus cancer during super selective intra-arterial cisplatin infusion and concomitant radiotherapy (RADPLAT)","volume":"17","author":"Ashida","year":"2021","journal-title":"Head Face Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.anl.2020.04.004","article-title":"Pathological evaluation of radiotherapy and concomitant intraarterial cisplatin for maxillary sinus cancer","volume":"47","author":"Makino","year":"2020","journal-title":"Auris Nasus Larynx."},{"key":"B59","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s11604-019-00827-1","article-title":"Radiation with concomitant superselective intra-arterial cisplatin infusion for maxillary sinus squamous cell carcinoma","volume":"37","author":"Ebara","year":"2019","journal-title":"Jpn J Radiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1945892418804904","article-title":"Practice patterns in office-based rhinology: survey of the American Rhinologic Society","volume":"33","author":"Lee","year":"2019","journal-title":"Am J Rhinol Allergy."},{"key":"B61","doi-asserted-by":"publisher","first-page":"285","DOI":"10.26355\/eurrev_201801_14170","article-title":"Use of balloon catheter dilation vs. traditional endoscopic sinus surgery in management of light and severe chronic rhinosinusitis of the frontal sinus: a multicenter prospective randomized study","volume":"22","author":"Minni","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/1945892420920505","article-title":"Exploring balloon sinuplasty adverse events with the innovative openFDA database","volume":"34","author":"Wright","year":"2020","journal-title":"Am J Rhinol Allergy."},{"key":"B63","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/000348941011900902","article-title":"Balloon catheter sinuplasty and adenoidectomy in children with chronic rhinosinusitis","volume":"119","author":"Ramadan","year":"2010","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/lary.27270","article-title":"Adenoidectomy with balloon catheter sinuplasty: a randomized trial for pediatric rhinosinusitis","volume":"128","author":"Gerber","year":"2018","journal-title":"Laryngoscope."},{"key":"B65","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0145561319840126","article-title":"Long-term effectiveness of balloon catheter sinuplasty in pediatric chronic maxillary sinusitis","volume":"98","author":"Zalzal","year":"2019","journal-title":"Ear Nose Throat J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0194599815613087","article-title":"Paranasal sinus balloon catheter dilation for treatment of chronic rhinosinusitis: a systematic review and meta-analysis","volume":"154","author":"Levy","year":"2016","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"B67","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1177\/1945892420917313","article-title":"Balloon catheter dilation in pediatric chronic rhinosinusitis: a meta-analysis","volume":"34","author":"Patel","year":"2020","journal-title":"Am J Rhinol Allergy."},{"key":"B68","doi-asserted-by":"publisher","first-page":"102627","DOI":"10.1016\/j.amjoto.2020.102627","article-title":"Medical data science in rhinology: background and implications for clinicians","volume":"41","author":"Jun","year":"2020","journal-title":"Am J Otolaryngol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1177\/0003489419863822","article-title":"Unsupervised learning techniques for the investigation of chronic rhinosinusitis","volume":"128","author":"Walker","year":"2021","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/alr.22452","article-title":"Virtual coach: the next tool in functional endoscopic sinus surgery education","volume":"10","author":"Richards","year":"2020","journal-title":"Int Forum Allergy Rhinol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/0194599818796476","article-title":"Applications of augmented reality in otolaryngology: a systematic review","volume":"159","author":"Wong","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41587-020-0726-6","article-title":"First video game to treat disease gains FDA okay","volume":"38","author":"Waltz","year":"2020","journal-title":"Nat Biotechnol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaerosci.2016.12.001","article-title":"Numerical investigation of the interaction, transport and deposition of multicomponent droplets in a simple mouth-throat model","volume":"105","author":"Chen","year":"2017","journal-title":"J Aerosol Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jhin.2021.04.029","article-title":"eHealth for the prevention of healthcare-associated infections: a scoping review","volume":"4","author":"Bentvelsen","year":"2021","journal-title":"J Hosp Infect"},{"key":"B75","doi-asserted-by":"publisher","first-page":"100389","DOI":"10.1016\/j.ajogmf.2021.100389","article-title":"Examining ultrasound diagnostic performance improvement with utilization of maternal-fetal medicine tele-interpretation","volume":"2021","author":"Kern-Goldberger","year":"2021","journal-title":"Am J Obstet Gynecol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jpsychires.2021.04.034","article-title":"An observational study of a cross platform risk assessment mobile application in a forensic inpatient setting","volume":"138","author":"McLoughlin","year":"2021","journal-title":"J Psychiatr Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/AHMT.S292977","article-title":"Virtual consultations: young people and their parents' experience","volume":"12","author":"Proulx-Cabana","year":"2021","journal-title":"Adolesc Health Med Ther Volume."},{"key":"B78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10916-021-01732-9","article-title":"Experiences in electronic consultation (eConsult) service in gynecology from a quaternary academic medical center","volume":"45","author":"Corbetta-Rastelli","year":"2021","journal-title":"J Med Syst."},{"key":"B79","doi-asserted-by":"publisher","first-page":"25140","DOI":"10.2196\/preprints.25140","article-title":"mHealth interventions for self-harm: a scoping review","volume":"23","author":"Cliffe","year":"2020","journal-title":"J Med Internet Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"PA735","DOI":"10.1183\/13993003.congress-2019.PA735","article-title":"Digital therapy in the treatment of asthma and COPD \u2013 epidemiology of development and use of an emerging health technology in Respiratory Medicine","volume":"2019","author":"Bodini","year":"2019","journal-title":"Eur Respiratory J"},{"key":"B81","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4193\/Rhin17.253","article-title":"Mysinusitiscoach: patient empowerment in chronic rhinosinusitis using mobile technology","volume":"56","author":"Seys","year":"2018","journal-title":"Rhinology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1111\/all.14408","article-title":"Real-life assessment of chronic rhinosinusitis patients using mobile technology: the mySinusitisCoach project by EUFOREA","volume":"75","author":"Seys","year":"2020","journal-title":"Allergy Eur J Allergy Clin Immunol."},{"key":"B83","unstructured":"Clinical Trial on Chronic Rhinosinusitis (Diagnosis): Video Education, Control - Clinical Trials Registry - ICH GCP.2021"},{"key":"B84","unstructured":"2021"},{"key":"B85","unstructured":"2021"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2021.732909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T05:54:54Z","timestamp":1639547694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2021.732909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":85,"alternative-id":["10.3389\/falgy.2021.732909"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2021.732909","relation":{},"ISSN":["2673-6101"],"issn-type":[{"type":"electronic","value":"2673-6101"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"732909"}}